Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC6022-0001 · 1 trial · 2 indications
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC6022-0001 | EXPERIMENTAL | Participants will be randomised to NNC6022-0001. |
| Placebo (NNC6022-0001) | PLACEBO_COMPARATOR | Participants will be randomised to placebo. |
| Name | Type | Description |
|---|---|---|
| NNC6022-0001 | DRUG | Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts. |
| Placebo (NNC6022-0001) | DRUG | Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts |
Inclusion Criteria: 1. Men or women of non-childbearing potential. 2. Age 18-55 years (both inclusive) at the time of signing the informed consent. 3. Body mass index (BMI) between 18.5 to 29.9 kg/m\^2 (both inclusive) at screening. 4. Body Weight: Greater than or equal to 50 kg at screening. 5. Co...
NNC6022-0001 is an investigational small molecule being developed by Novo Nordisk for cardiovascular conditions. It is currently in Phase 1 clinical trials, where it is being studied in healthy volunteers to assess its safety and tolerability. The study also includes participants with cardiometabolic diseases, indicating potential future applications in this area.
The specific molecular target of NNC6022-0001 has not been disclosed. It is a small molecule being developed for cardiovascular indications, but its mechanism of action is not publicly available at this time. The ongoing Phase 1 trial is focused on evaluating the safety and tolerability of the drug in healthy volunteers.
NNC6022-0001 is developed by Novo Nordisk A/S, a global healthcare company traded on the New York Stock Exchange under the ticker symbol NVO. The company is conducting clinical research on this investigational small molecule for cardiovascular indications.
NNC6022-0001 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing to evaluate its safety in humans.
NNC6022-0001 has one completed Phase 1 clinical trial registered as NCT06336005. This randomized, double-blind, placebo-controlled study enrolled 56 participants in the Netherlands to evaluate the safety of the drug in healthy volunteers and individuals with cardiometabolic diseases. The trial has been completed.